Serum urate is associated with an increased risk of inflammatory bowel disease : A bidirectional Mendelian randomization study
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved..
BACKGROUND: Previous studies have indicated bidirectional associations between urate levels and inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD). However, it remains unclear whether the observations are causal because of confounding factors.
AIM: To investigate the causal associations between urate levels and IBD using bidirectional Mendelian randomization (MR).
METHODS: Independent genetic variants for urate levels and IBD were selected as instrumental variables from published genome-wide association studies (GWASs). Summary statistics for instrument-outcome associations were retrieved from three separate databases for IBD (the UK Biobank, the FinnGen database and a large GWAS meta-analysis) and one for urate levels (a large GWAS meta-analysis). MR analyses included the inverse-variance-weighted method, weighted-median estimator, MR-Egger and sensitivity analyses (MR-PRESSO). A meta-analysis was also conducted to merge the data from separate outcome databases using a fixed-effects model.
RESULTS: Genetically higher serum urate levels were strongly associated with an increased risk of UC [odds ratio (OR): 1.95, 95% confidence interval (CI): 1.86-2.05] after outlier correction, and the ORs (95%CIs) for IBD and CD were 0.94 (95%CI: 0.86-1.03) and 0.91 (95%CI: 0.80-1.04), respectively. Animal studies have confirmed the positive association between urate levels and UC. Moreover, genetically predicted IBD was inversely related to urate levels (OR: 0.97, 95%CI: 0.94-0.99). However, no association was observed between genetically influenced UC or CD and urate levels.
CONCLUSION: Urate levels might be risk factors for UC, whereas genetically predicted IBD was inversely associated with urate levels. These findings provide essential new insight for treating and preventing IBD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
World journal of clinical cases - 12(2024), 5 vom: 16. Feb., Seite 891-902 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Song [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antioxidant |
|---|
| Anmerkungen: |
Date Revised 29.02.2024 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.12998/wjcc.v12.i5.891 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369045319 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369045319 | ||
| 003 | DE-627 | ||
| 005 | 20240229235436.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.12998/wjcc.v12.i5.891 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1311.xml |
| 035 | |a (DE-627)NLM369045319 | ||
| 035 | |a (NLM)38414603 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Song |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serum urate is associated with an increased risk of inflammatory bowel disease |b A bidirectional Mendelian randomization study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 29.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Previous studies have indicated bidirectional associations between urate levels and inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD). However, it remains unclear whether the observations are causal because of confounding factors | ||
| 520 | |a AIM: To investigate the causal associations between urate levels and IBD using bidirectional Mendelian randomization (MR) | ||
| 520 | |a METHODS: Independent genetic variants for urate levels and IBD were selected as instrumental variables from published genome-wide association studies (GWASs). Summary statistics for instrument-outcome associations were retrieved from three separate databases for IBD (the UK Biobank, the FinnGen database and a large GWAS meta-analysis) and one for urate levels (a large GWAS meta-analysis). MR analyses included the inverse-variance-weighted method, weighted-median estimator, MR-Egger and sensitivity analyses (MR-PRESSO). A meta-analysis was also conducted to merge the data from separate outcome databases using a fixed-effects model | ||
| 520 | |a RESULTS: Genetically higher serum urate levels were strongly associated with an increased risk of UC [odds ratio (OR): 1.95, 95% confidence interval (CI): 1.86-2.05] after outlier correction, and the ORs (95%CIs) for IBD and CD were 0.94 (95%CI: 0.86-1.03) and 0.91 (95%CI: 0.80-1.04), respectively. Animal studies have confirmed the positive association between urate levels and UC. Moreover, genetically predicted IBD was inversely related to urate levels (OR: 0.97, 95%CI: 0.94-0.99). However, no association was observed between genetically influenced UC or CD and urate levels | ||
| 520 | |a CONCLUSION: Urate levels might be risk factors for UC, whereas genetically predicted IBD was inversely associated with urate levels. These findings provide essential new insight for treating and preventing IBD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antioxidant | |
| 650 | 4 | |a Inflammatory bowel disease | |
| 650 | 4 | |a Mendelian randomization | |
| 650 | 4 | |a Single nucleotide polymorphism | |
| 650 | 4 | |a Urate levels | |
| 700 | 1 | |a Fang, Xue |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Le |e verfasserin |4 aut | |
| 700 | 1 | |a Sui, Xiang-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Miao |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Yu-Jia |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Shuo |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Zhao-Shen |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Sheng-Bing |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Yu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World journal of clinical cases |d 2013 |g 12(2024), 5 vom: 16. Feb., Seite 891-902 |w (DE-627)NLM233331727 |x 2307-8960 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2024 |g number:5 |g day:16 |g month:02 |g pages:891-902 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.12998/wjcc.v12.i5.891 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2024 |e 5 |b 16 |c 02 |h 891-902 | ||